Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stevanato Group excels in 2022, eyes high value solutions growth

Stevanato Group's strong financial performance in 2022, driven by high value solutions and operational efficiency, sets a solid foundation for future growth.
Strategic focus on biologics and high growth markets, along with optimized capital spending, positions the company for long-term success.
Challenges in pricing management and capacity ramp-up require careful navigation, while opportunities in expanding high value solutions and market demand offer avenues for growth.
Overall, Stevanato Group's performance reflects resilience, strategic foresight, and a commitment to value creation, signaling a positive trajectory for the company.

Stevanato Group reports strong Q1 results, eyes biologics market growth

Stevanato Group's Q1 performance reflects robust revenue growth, profitability, and a strong order backlog, underpinned by strategic collaborations and market focus.
While facing challenges such as pricing pressures and market dynamics, the company is well-positioned to leverage opportunities in the biologics sector and innovative drug delivery solutions.
With a reiterated full-year revenue guidance and a focus on operational excellence, Stevanato Group demonstrates resilience and strategic foresight in navigating the evolving healthcare landscape.
Investors can find confidence in the company's performance, strategic strengths, and growth opportunities amidst the challenges and uncertainties in the market.

Stevanato Group SpA reports robust Q2 performance and eyes growth

Stevanato Group SpA's Q2 2023 earnings call highlighted strong performance, growth prospects, and strategic initiatives amidst market challenges.
The company's financial results, revenue breakdown, and guidance underscore its resilience and potential for sustained growth.
Addressing challenges like currency fluctuations and market dynamics while seizing growth opportunities will be key for Stevanato Group SpA's future success.

Stevanato Group reports strong Q3 earnings, eyes biologics market growth

Stevanato Group's Q3 2023 performance showcased robust revenue growth and margin expansion, despite challenges in specific segments. The company's strong presence in key biologics markets and strategic priorities for sustainable growth position it well for the future. Opportunities in expanding markets and a solid order backlog provide a positive outlook.

Stevanato Group reports 10% revenue growth in Q4 2023

Stevanato Group's 2023 performance reflects growth driven by high-value solutions and strong demand.
Despite challenges like margin pressure and supply chain issues, the company remains confident in achieving growth.
Opportunities lie in expanding capacity, enhancing product mix, and capitalizing on backlog growth.
The company anticipates a stronger second half of 2024 and foresees material revenue impact from biologic products in 2025.

Stevanato Group faces Q1 challenges, invests in growth opportunities

Stevanato Group's Q1 2024 performance was impacted by industry-wide challenges, but the company remains focused on strategic priorities and operational efficiencies.
Despite revenue decline and margin impacts, the company's commitment to growth through expansion projects and high-value solutions showcases resilience and forward-thinking.
Challenges in vial demand and customer delays are being addressed through cost management and strategic actions, while opportunities in new investments and operational focus are being pursued.
The company's leadership position, solid strategy, and emphasis on execution position Stevanato Group for long-term success despite near-term headwinds.

Stevanato Group reports modest revenue growth amidst margin challenges

Stevanato Group delivered mixed results in Q2, with revenue growth driven by the Biopharmaceutical and Diagnostic Solutions segment.
While facing margin pressures and operational challenges, the company's focus on high-value solutions and efficiency improvements bodes well for long-term prospects.
Navigating through current obstacles, Stevanato Group remains optimistic about its ability to drive growth and enhance profitability.

Stevanato Group adjusts guidance amidst challenges, eyes growth opportunities

Stevanato Group's Q3 2024 performance was impacted by challenges in Engineering and the U.S., leading to a revised full-year guidance.
Despite operational challenges, the company demonstrated strengths in capacity expansion, innovation, and revenue growth.
Addressing challenges in vial destocking and segment optimization presents opportunities for future growth and profitability.
Analyst questions highlighted the need to navigate current challenges while capitalizing on opportunities for strategic advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Q4 and FY 2021 STVN Earnings

Stevanato Group Reports Record 2021 Revenue of €843.9 million

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its subsidiary, OMPI of America Inc., entered into an agreement to support the Biomedical Advanced Research and Development Authority (“BARDA”, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human S

Stevanato Group Announces Agreement With BARDA for the Expansion of Vial Production to Create Industrial Base Capabilities for National Defense

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Q4 & YE 2021 Earnings notification

Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, acceler

Stevanato Group Appoints Riccardo Butta as President, Americas

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D™ pen injector technology. The extension gives the company exclusivity to offer the technology to support a broader range of drugs for its biopharma customers beyond diabetes, including

Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Gr

Stevanato Group Announces Expansion of Corporate Headquarters

Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q3 2021 Results - Earnings Call Transcript

Italian vaccine vial maker Stevanato on Tuesday slightly improved its guidance on full-year results after reporting a 37% increase in third quarter revenue.

Vaccine vial maker Stevanato ticks up 2021 guidance after Q3 results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--STVN Q3 21

Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the third quarter of fiscal 2021 on Tuesday, November 9, 2021 at 6:30 a.m. Eastern Time (12:30 CET). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET)

Stevanato Group to Report Third Quarter Financial Results on November 9

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has been recognized as a winner of Pharma Manufacturing magazine's 2021 Pharma Innovation Award for its AI-ready Vision Robot Unit (VRU) - a robotic human-like inspection unit. Stevanato Group's VRU inspection system is an autonomous module capable of automatically

Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an a

Stevanato Group Initiates Construction on New U.S. Facility

Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q2 2021 Results - Earnings Call Transcript

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance. Second Quarter 2021 Highlights (compared to the same period last year) and Guidance Revenue grew 26% to €204.0 million; all growth was organic Gross margins incr

Stevanato Group Announces Second Quarter 2021 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that the underwriters of the Company's recently completed initial public offering of its ordinary shares have exercised in part their option to acquire an additional 1,018,280 ordinary shares at $21 a share. The offering resulted in net proceeds of ap

Stevanato Group Announces Underwriters' Partial Exercise of Over-Allotment Option

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021. The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on August 19, 2021. Management w

Stevanato Group to Report Second Quarter Financial Results on August 19

Blend Labs

Bridge Investment Group Holdings

Erasca Inc

Imago Biosciences

Regencell Bioscience Holdings Ltd

The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.

7 Companies Begin Trading. Here's How They're Doing.

(Reuters) -Shares of Italy's Stevanato Group S.p.A., which makes glass vials for COVID-19 vaccines and other healthcare products, fell more than 20% in their New York Stock Exchange debut, giving the company a market capitalization of over $5 billion.

Vaccine vial maker Stevanato valued at over $5 billion in NYSE debut

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”) today celebrates its debut on the New York Stock Exchange under the ticker symbol “STVN.” Founded by Giovanni Stevanato in 1949, the Company is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. “It is an honor for Stevanato Group to join the New York Stock Exchange and begin the next chapter in our storied history,”

Stevanato Group Celebrates Initial Public Offering and First Day of Public Trading on New York Stock Exchange (NYSE)

Stevanato Group S.p.A., an Italian maker of glass vials for COVID-19 vaccines and other healthcare products, raised $672 million in a downsized initial public offering on Thursday.

Vaccine vial maker Stevanato raises $672 million in U.S. IPO

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its initial public offering of 32,000,000 of its ordinary shares at a price of $21 per share. The shares are expected to begin trading on the New York Stock Exchange on July 16, 2021, under the ticker symbol “STVN.” The offering is expe

News for Stevanato Group SpA Stock (STVN)